Compare Stocks: CMMB, ATYR, EDSA, and TIL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$0.56 +1.1%	$0.52	$0.40 ▼ $6.50	$54.24M	0.54	729,733 shs	656,608 shs
CMMB Chemomab Therapeutics	$1.91 +0.5%	$1.70	$1.35 ▼ $4.12	$13.68M	0.65	68,059 shs	21,557 shs
EDSA Edesa Biotech	$5.35 -1.5%	$6.29	$0.72 ▼ $20.32	$52.31M	1.08	57,315 shs	45,953 shs
TIL Instil Bio	$7.38 +1.5%	$7.52	$5.67 ▼ $33.83	$49.31M	1.94	9,458 shs	13,524 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	+1.08%	+9.31%	+4.62%	+10.91%	-89.15%
CMMB Chemomab Therapeutics	+0.53%	-1.04%	+25.66%	+15.06%	-50.16%
EDSA Edesa Biotech	-1.47%	+1.52%	-22.13%	-59.00%	+144.29%
TIL Instil Bio	+1.51%	-0.40%	-3.15%	-8.55%	-72.64%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$0.56 +1.1%	$0.52	$0.40 ▼ $6.50	$54.24M	0.54	729,733 shs	656,608 shs
CMMB Chemomab Therapeutics	$1.91 +0.5%	$1.70	$1.35 ▼ $4.12	$13.68M	0.65	68,059 shs	21,557 shs
EDSA Edesa Biotech	$5.35 -1.5%	$6.29	$0.72 ▼ $20.32	$52.31M	1.08	57,315 shs	45,953 shs
TIL Instil Bio	$7.38 +1.5%	$7.52	$5.67 ▼ $33.83	$49.31M	1.94	9,458 shs	13,524 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	+1.08%	+9.31%	+4.62%	+10.91%	-89.15%
CMMB Chemomab Therapeutics	+0.53%	-1.04%	+25.66%	+15.06%	-50.16%
EDSA Edesa Biotech	-1.47%	+1.52%	-22.13%	-59.00%	+144.29%
TIL Instil Bio	+1.51%	-0.40%	-3.15%	-8.55%	-72.64%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	2.25	Hold	$17.00	2,941.14% Upside
CMMB Chemomab Therapeutics	2.00	Hold	$25.00	1,208.90% Upside
EDSA Edesa Biotech	2.67	Moderate Buy	$5.00	-6.54% Downside
TIL Instil Bio	1.67	Reduce	$66.00	794.31% Upside

Current Analyst Ratings Breakdown

Latest CMMB, ATYR, EDSA, and TIL Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/5/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/31/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/16/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/15/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/29/2026	EDSA Edesa Biotech	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	EDSA Edesa Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	TIL Instil Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/22/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/20/2026	ATYR aTyr Pharma	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	$190K	288.59	N/A	N/A	$0.50 per share	1.12
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$2.00 per share	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	$0.45 per share	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	$16.79 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$74.12M	-$0.62	N/A	N/A	N/A	N/A	-95.89%	-69.67%	N/A
CMMB Chemomab Therapeutics	-$8.99M	-$2.22	N/A	N/A	N/A	N/A	-89.03%	-79.68%	N/A
EDSA Edesa Biotech	-$7.19M	-$1.34	N/A	N/A	N/A	N/A	-437.50%	-104.14%	N/A
TIL Instil Bio	-$71.37M	-$7.08	N/A	N/A	N/A	N/A	-26.33%	-14.75%	N/A

Latest CMMB, ATYR, EDSA, and TIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q3 2026	EDSA Edesa Biotech	-$0.4350	-$0.60	-$0.1650	-$0.60	N/A	N/A
8/13/2026	Q2 2026	TIL Instil Bio	-$0.35	-$0.63	-$0.28	-$0.63	N/A	N/A
8/7/2026	Q2 2026	ATYR aTyr Pharma	-$0.1214	-$0.11	+$0.0114	-$0.11	N/A	$189.56 million
5/15/2026	Q1 2026	ATYR aTyr Pharma	-$0.16	-$0.11	+$0.05	-$0.11	N/A	N/A
5/15/2026	Q1 2026	TIL Instil Bio	-$0.62	-$0.62	N/A	-$0.62	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	N/A	5.12	5.78
CMMB Chemomab Therapeutics	N/A	10.31	10.31
EDSA Edesa Biotech	N/A	4.76	4.76
TIL Instil Bio	0.77	39.87	39.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
CMMB Chemomab Therapeutics	46.05%
EDSA Edesa Biotech	5.50%
TIL Instil Bio	60.56%

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	5.75%
CMMB Chemomab Therapeutics	11.91%
EDSA Edesa Biotech	24.40%
TIL Instil Bio	47.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	53	98.09 million	92.45 million	Optionable
CMMB Chemomab Therapeutics	20	7.20 million	6.34 million	Not Optionable
EDSA Edesa Biotech	20	9.63 million	7.28 million	Not Optionable
TIL Instil Bio	410	6.78 million	3.59 million	No Data

CMMB, ATYR, EDSA, and TIL Headlines

Recent News About These Companies

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 13 at 5:00 PM | globenewswire.com

Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)

July 16, 2026 | seekingalpha.com

Instil Bio Shareholders Back Directors and Auditor at Meeting

June 11, 2026 | tipranks.com

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 15, 2026 | globenewswire.com

Instil Bio (TIL) Price Target Increased by 24.53% to 67.32

April 9, 2026 | msn.com

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 27, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

February 12, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

February 3, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 29, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio,

January 27, 2026 | bakersfield.comB

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 27, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 22, 2026 | prnewswire.com

TIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & Korsinsky

January 20, 2026 | newsfilecorp.comN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 20, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 15, 2026 | prnewswire.com

Instil Bio (TIL) Price Target Decreased by 45.17% to 53.55

January 14, 2026 | msn.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 13, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

January 8, 2026 | prnewswire.com

HC Wainwright & Co. downgrades Instil Bio (TIL)

January 8, 2026 | msn.com

Arrowhead showcases early obesity data; Instil bails on PD-1/VEGF drug

January 7, 2026 | biopharmadive.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB, ATYR, EDSA, and TIL Company Descriptions

aTyr Pharma NASDAQ:ATYR

$0.56 +0.01 (+1.08%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.56 0.00 (-0.72%)

As of 08/14/2026 07:30 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Chemomab Therapeutics NASDAQ:CMMB

$1.91 +0.01 (+0.53%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.90 0.00 (-0.26%)

As of 08/14/2026 04:19 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Edesa Biotech NASDAQ:EDSA

$5.35 -0.08 (-1.47%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$5.61 +0.26 (+4.86%)

As of 08/14/2026 07:59 PM Eastern

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Instil Bio NASDAQ:TIL

$7.38 +0.11 (+1.51%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$7.37 -0.01 (-0.14%)

As of 08/14/2026 07:34 PM Eastern

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMMB, ATYR, EDSA, and TIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMMB, ATYR, EDSA, and TIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMMB, ATYR, EDSA, and TIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB, ATYR, EDSA, and TIL Company Descriptions

aTyr Pharma NASDAQ:ATYR

Chemomab Therapeutics NASDAQ:CMMB

Edesa Biotech NASDAQ:EDSA

Instil Bio NASDAQ:TIL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMMB, ATYR, EDSA, and TIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMMB, ATYR, EDSA, and TIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMMB, ATYR, EDSA, and TIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB, ATYR, EDSA, and TIL Company Descriptions

aTyr Pharma NASDAQ:ATYR

Chemomab Therapeutics NASDAQ:CMMB

Edesa Biotech NASDAQ:EDSA

Instil Bio NASDAQ:TIL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools